Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer

被引：0
|
作者：
Kikuchi, Y., Sr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kouta, H. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kikuchi, R. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Takano, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kita, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Kudoh, K. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Aoki, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Sugiyama, T. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Isonishi, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Ohki Mem Kikuchi Canc Clin Women, Tokorozawa, Saitama, Japan
[2] Natl Def Med Coll, Tokorozawa, Saitama 359, Japan
[3] Teikyo Univ, Sch Med, Tokyo 173, Japan
[4] Nishisaitama Cent Hosp, Tokorozawa, Saitama, Japan
[5] Keio Univ, Sch Med, Tokyo, Japan
[6] Iwate Med Univ, Morioka, Iwate 020, Japan
[7] Jikei Univ, Sch Med, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5547
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin in ovarian cancer treatment
    Nowak-Markwitz, Ewa
    GINEKOLOGIA POLSKA, 2009, 80 (08) : 615 - 619
  • [32] Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients - May a new treatment schedule improve toxicity profile?
    Lorusso, D
    Naldini, A
    Testa, A
    D'Agostino, G
    Scambia, G
    Ferrandina, G
    ONCOLOGY, 2004, 67 (3-4) : 243 - 249
  • [33] Pegylated liposomal doxorubicin in the management of ovarian cancer
    Ferrandina, Gabriella
    Corrado, Giacomo
    Licameli, Angelo
    Lorusso, Domenica
    Fuoco, Gilda
    Pisconti, Salvatore
    Scambia, Giovanni
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 463 - 483
  • [34] Pegylated Liposomal Doxorubicin in the Management of Ovarian Cancer
    Ferrandina, Gabriella
    Petrillo, Marco
    Licameli, Angelo
    Fuoco, Gilda
    Scambia, Giovanni
    Corrado, Giacomo
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2010, 2 : 261 - 270
  • [35] Role of pegylated liposomal doxorubicin in ovarian cancer
    Thigpen, JT
    Aghajanian, CA
    Alberts, DS
    Campos, SM
    Gordon, AN
    Markman, M
    McMeekin, DS
    Monk, BJ
    Rose, PG
    GYNECOLOGIC ONCOLOGY, 2005, 96 (01) : 10 - 18
  • [36] Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer
    Inaba, Kanako
    Arimoto, Takahide
    Hoya, Mari
    Kawana, Kei
    Nakagawa, Shunsuke
    Kozuma, Shiro
    Taketani, Yuji
    MEDICAL ONCOLOGY, 2012, 29 (02) : 1255 - 1257
  • [37] Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis
    Lorusso, Domenica
    Sabatucci, Ilaria
    Maltese, Giuseppa
    Lepori, Stefano
    Tripodi, Elisa
    Bogani, Giorgio
    Raspagliesi, Francesco
    TUMORI JOURNAL, 2019, 105 (04): : 282 - 287
  • [38] Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer
    Kanako Inaba
    Takahide Arimoto
    Mari Hoya
    Kei Kawana
    Shunsuke Nakagawa
    Shiro Kozuma
    Yuji Taketani
    Medical Oncology, 2012, 29 : 1255 - 1257
  • [39] Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
    Jehn, Christian F.
    Hemmati, Philipp
    Lehenbauer-Dehm, Silvia
    Kuemmel, Sherko
    Flath, Bernd
    Schmid, Peter
    CLINICAL BREAST CANCER, 2016, 16 (06) : 514 - 519
  • [40] Weekly Non-pegylated Liposomal Doxorubicin Chemotherapy in Heavily Pre-treated Patients with Metastatic Breast Cancer
    Masci, Giovanna
    Gandini, Chiara
    Zuradelli, Monica
    Losurdo, Agnese
    Torrisi, Rosalba
    Rota, Selene
    Gullo, Giuseppe
    Velutti, Laura
    Giordano, Laura
    Santoro, Armando
    ANTICANCER RESEARCH, 2013, 33 (10) : 4603 - 4609
12345